About Praxis Precision Medicines
Praxis Precision Medicines is a company based in Cambridge (United States) founded in 2015. Praxis Precision Medicines has raised $110 million across 1 funding round from investors including Blackstone, Citadel and Verition Fund Management. The company has 116 employees as of December 31, 2024. Praxis Precision Medicines offers products and services including Precision Therapies and Clinical Assets. Praxis Precision Medicines operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Cambridge, United States
- Employees 116 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Praxis Precision Medicines, Inc.
-
Annual Revenue
$8.55 M (USD)249.53as on Dec 31, 2024
-
Net Profit
-$182.82 M (USD)-48.3as on Dec 31, 2024
-
EBITDA
-$199.81 M (USD)-58.65as on Dec 31, 2024
-
Total Equity Funding
$110 M (USD)
in 1 rounds
-
Latest Funding Round
$110 M (USD), Series C
May 04, 2020
-
Investors
Blackstone
& 11 more
-
Employee Count
116
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Praxis Precision Medicines
Praxis Precision Medicines is a publicly listed company on the NASDAQ with ticker symbol PRAX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Praxis Precision Medicines
Praxis Precision Medicines offers a comprehensive portfolio of products and services, including Precision Therapies and Clinical Assets.
Develops treatments for CNS disorders based on genetic insights.
Advances programs like EMBOLD for epilepsy treatment via genetics.
People of Praxis Precision Medicines
Unlock access to complete
Unlock access to complete
Leadership Team
14 people
Software Development Team
10 people
Operations Team
6 people
Finance and Accounting
6 people
Human Resources and Administration
4 people
Product Management Team
4 people
Sales and Marketing
3 people
Senior Team
3 people
Unlock access to complete
Funding Insights of Praxis Precision Medicines
Praxis Precision Medicines has successfully raised a total of $110M through 1 strategic funding round. The most recent funding activity was a Series C round of $110 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Praxis Precision Medicines
Praxis Precision Medicines has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Citadel and Verition Fund Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Biomedical innovations are transformed into therapies by Vida Ventures.
|
Locked | Locked | Locked |
Investor details for Praxis Precision Medicines
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Praxis Precision Medicines
Investment portfolio details for Praxis Precision Medicines
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Praxis Precision Medicines
Detailed financials for Praxis Precision Medicines
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Praxis Precision Medicines Comparisons
Peer comparison for Praxis Precision Medicines
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Praxis Precision Medicines
Praxis Precision Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Praxis Precision Medicines
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Praxis Precision Medicines
Complete news archive for Praxis Precision Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Praxis Precision Medicines
Praxis Precision Medicines was founded in 2015 and raised its 1st funding round 5 years after it was founded.
Praxis Precision Medicines is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Marcio Souza is the current CEO of Praxis Precision Medicines.
Praxis Precision Medicines is a funded company, having raised a total of $110M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Praxis Precision Medicines is 116.
Annual revenue of Praxis Precision Medicines is $8.55M as on Dec 31, 2024.
Praxis Precision Medicines was founded in 2015 and is headquartered in Cambridge, United States. Therapies targeting brain disorders are developed within the biotechnology sector. Key candidates include Prax-114 for mood disorders, Prax-994 for movement disorders such as epilepsy, Prax-222 and Prx-120 for genetic epilepsies, and Prax-562 for pain disorders. Operations focus on advancing these treatments through research and development. Leadership is provided by CEO and President Marcio Souza.
Praxis Precision Medicines's top competitors include Jazz Pharmaceuticals, Biohaven Pharmaceutical and Sana Biotechnology.
Praxis Precision Medicines offers Precision Therapies and Clinical Assets.
Yes, Praxis Precision Medicines is publicly traded on NASDAQ under the ticker symbol PRAX.
Praxis Precision Medicines has 12 investors. Key investors include Blackstone, Citadel, Verition Fund Management, Novo Holdings, and Vida Ventures.
The ticker symbol of Praxis Precision Medicines is PRAX on NASDAQ.